TD is clinically distinct
Know the signsTD may be disruptive
Find out moreTD remains common
Learn moreMechanism
Learn moreAssess patients for TD
See profilesReductions in TD severity
View efficacyClinical study design
Find out moreSafety profile
View safetyAdverse reactions by dose
Find out moreSafety assessment scales
Learn moreConvenient once-daily dosing
Prescribe withconfidence
Drug interactions
Find out moreAdministration information
Learn moreINGREZZA support
Partner withINBRACE™
Instant resources
Find out moreVideo library
Watch videosRegister
SIGN UP
Why INGREZZA?
Important Information
INDICATION & USAGE
INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.
WARNINGS & PRECAUTIONS
Somnolence
INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.
QT Prolongation
INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.
ADVERSE REACTIONS
The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see INGREZZA full Prescribing Information or visit www.INGREZZAHCP.com
View Full Important Safety Information
Important Information
INDICATION & USAGE
INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.
WARNINGS & PRECAUTIONS
Somnolence
INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.
QT Prolongation
INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.
ADVERSE REACTIONS
The most common adverse reaction (≥5% and twice the rate of placebo) is somnolence. Other adverse reactions (≥2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
Please see INGREZZA full Prescribing Information or visit www.INGREZZAHCP.com
REFERENCE: INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc; 2018.
Back to Top
Receive information from a
Neurocrine Biosciences representative
To receive information about INGREZZA® (valbenazine) capsules, please complete the form below. You should receive a response within 2 business days. Your information will only be used to respond to your information request. Additionally, you can uncheck the box below if you prefer not to register for other updates on INGREZZA.
Thank you for your request.
A Neurocrine Biosciences representative will contact you within 2 business days.
Video description3
Actor portrayals of TD movements were completed in the presence of a movement disorder neurologist who assessed each movement for severity from 0 (no dyskinesia) to 4 (severe dyskinesia) using Items 1 through 7 of the Abnormal Involuntary Movement Scale (AIMS).
Subscores for baseline video
